NCT00427856 2016-07-22
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
Clinical Trials
9 trialsNCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00407303 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00438178 2014-05-12
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00600964 2014-05-12
A Phase I/II Study of GX15-070MS in Untreated CLL
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT00684918 2013-08-26
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01563601 2012-08-15
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Withdrawn